Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Precise Design CAR-T for Relapsed/Refractory Hematological Tumors
NCT06849921Phase 1Active, not recruiting
- Sponsor
- Ruijin Hospital
- Start
- Nov 2024
- Primary completion
- Dec 2030
- Modality
- Gene Editing, Gene Silencing, CAR-T Cells
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of Precise Design CAR-T in hematologic malignancy, sponsored by Ruijin Hospital. Primary endpoints: Adverse Events at 1 month, Maximum Tolerated Dose at 1 month and 1 more. Started Nov 2024; status: active, not recruiting.
02
Drugs
Precise Design CAR-T
03
Conditions
hematologic malignancy
Beyond the preview
Go deeper on NCT06849921.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06849921.